# Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

Study · id `cardio:ct-nct01956786` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01956786](<https://clinicaltrials.gov/study/NCT01956786>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01956786

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 540 participants.

## Technical summary

Registry record NCT01956786. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 540 participants (planned count; ClinicalTrials.gov record NCT01956786, source copy `cardio:ctgov-nct01956786-2013-10-08`, retrieved 2026-10-26)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01956786, source copy `cardio:ctgov-nct01956786-2013-10-08`, retrieved 2026-10-26)
- Primary completion: 2013-12 (anticipated) (ClinicalTrials.gov record NCT01956786, source copy `cardio:ctgov-nct01956786-2013-10-08`, retrieved 2026-10-26)
- Completion: 2014-02 (anticipated) (ClinicalTrials.gov record NCT01956786, source copy `cardio:ctgov-nct01956786-2013-10-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01956786, source copy `cardio:ctgov-nct01956786-2013-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01956786-2013-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
- Condition: Essential Hypertension
- Intervention (Drug): Amlodipine-FA tablet,low dose group
- Intervention (Drug): Amlodipine-FA tablet,high dose group
- Intervention (Drug): Amlodipine
- Lead sponsor: Shenzhen Ausa Pharmed Co.,Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Ruijin Hospital
- Collaborator class: OTHER
- Collaborator: Second Affiliated Hospital of Nanchang University
- Collaborator class: OTHER
- Collaborator: Xuzhou Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry lists this organization as the lead sponsor: Shenzhen Ausa Pharmed Co.,Ltd (`cardio:org-shenzhen-ausa-pharmed-co-ltd`)
- Registry lists this organization as a collaborator: Ruijin Hospital (`cardio:org-ruijin-hospital`)
- Registry lists this organization as a collaborator: Second Affiliated Hospital of Nanchang University (`cardio:org-second-affiliated-hospital-of-nanchang-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double-blind, parallel-controlled clinical trial (`cardio:pubmed-37433173`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4c2f08b73e37e7d1a978d09a39403427d9a6c1762d76caf4bd5cc22726a86c06
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
